PYC On Other Exchanges

physiomics plc (PYC) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PHYSIOMICS PLC (PYC)

Related News

No related news articles were found.

physiomics plc (PYC) Related Businessweek News

No Related Businessweek News Found

physiomics plc (PYC) Details

Physiomics Plc provides outsourced systems and computational biology services to pharmaceutical companies in the United Kingdom, the European Union, and the United States. It offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. The company also develops technology for use in the field of personalized medicine. Physiomics Plc is based in Oxford, the United Kingdom.

6 Employees
Last Reported Date: 10/15/18

physiomics plc (PYC) Top Compensated Officers

CEO & Director
Total Annual Compensation: 131.3K GBP
COO & Executive Director
Total Annual Compensation: 66.0K GBP
Compensation as of Fiscal Year 2017.
physiomics plc
Physiomics Plc Presents at BioTrinity 2019, Apr-30-2019

Physiomics Plc Presents at BioTrinity 2019, Apr-30-2019 . Venue: London, United Kingdom.

Physiomics Plc Presents at 2019 American Association for Cancer Research (AACR) Annual Meeting, Mar-31-2019 01:00 PM

Physiomics Plc Presents at 2019 American Association for Cancer Research (AACR) Annual Meeting, Mar-31-2019 01:00 PM. Venue: Georgia World Congress Center, Atlanta, Georgia, United States.

Physiomics Plc Presents on Personalised Medicine and Virtual Tumour™ Developments at AACR 2019 Meeting

Physiomics Plc announced that it is participating in the American Academy of Cancer Research ("AACR") Annual Meeting 2019, taking place in Atlanta, Georgia, 29th March to 3rd April. The company will for the first time be presenting on two new topics arising from client and grant funded projects. Physiomics will have a significant presence at the conference including a stand in the main meeting hall (booth #1851). In addition, the company will be presenting two original posters in the session "PO.BSB02.01 - Convergence Science for Therapeutics and Precision Medicine"-Section 30, scheduled 31st March 2019, 1:00 PM - 5:00 PM: A precision dosing application for prostate cancer chemotherapy (Abstract #677): This is company's first tool based on AI (machine learning) technologies. Currently dosing of docetaxel in prostate cancer is based on population averages, leading to effective under or over dosing in a significant number of patients. Company's tool could, if approved, provide information that could assist clinicians in adapting chemotherapy dosing for individual patients. This offers the possibility of enhancing both the safety and efficacy of an existing standard of care without the costs typically associated with a new pharmaceutical product. Predicting the effect of radiotherapy on tumour growth inhibition and time to progression in head and neck cancer (Abstract #680): Over recent years, driven by a number of actual client projects, company have extended Virtual Tumour™ technology from a tool primarily used to predict preclinical tumour growth inhibition into one that can also help clients understand the likely response to their drug(s) in the clinic. The most recent evolution of Virtual Tumour™ has been to enhance its ability to model the longer-term re-growth of clinical tumours which can exhibit widely varying times to re-growth/progression following irradiation. As time to progression is the strongest predictor of survival, company believe that this enhanced capability increases the value of company's predictions to company's clients.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

PYC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PYC.
View Industry Companies

Industry Analysis


Industry Average

Valuation PYC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.1x
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.1x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact PHYSIOMICS PLC, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at